Nature Communications · 2024 · 24 citations · 68 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyCancer ImmunotherapyOncogenic VirusesOncology PharmacologyOncolytic Virus TherapyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityAntiviral Cytokine ResponsesInflammatory Mediator PathwaysOncolytic Viral TherapyOncolytic Virus CombinationsPro-inflammatory Signaling Pathways
The presence of heterogeneity in responses to oncolytic virotherapy poses a barrier to clinical effectiveness, as resistance to this treatment can occur through the inhibition of viral spread within the tumor, potentially leading to treatment failures. Here we show that 4-octyl itaconate (4-OI), a chemical derivative of the Krebs cycle-derived metabolite itaconate, enhances oncolytic virotherapy with VSVΔ51 in various models including human and murine resistant cancer cell lines, three-dimensional (3D) patient-derived colon tumoroids and organotypic brain tumor slices. Furthermore, 4-OI in combination with VSVΔ51 improves therapeutic outcomes in a resistant murine colon tumor model. Mechanistically, we find that 4-OI suppresses antiviral immunity in cancer cells through the modification of cysteine residues in MAVS and IKKβ independently of the NRF2/KEAP1 axis. We propose that the combination of a metabolite-derived drug with an oncolytic virus agent can greatly improve anticancer therapeutic outcomes by direct interference with the type I IFN and NF-κB-mediated antiviral responses.
68
World Medical Association Declaration of Helsinki
JAMA · 2013 · 29.4K citations
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Mihaela Pertea, Geo Pertea, Corina Antonescu et al. · Nature Biotechnology · 2015 · 15.5K citations · Full text